Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

60.0%

-26.6% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
4(80.0%)
Phase 1
1(20.0%)
5Total
Phase 2(4)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT01252199Phase 2Completed

Study of Chimeric Monoclonal Antibodies to Shiga Toxins 1 and 2

Role: lead

NCT00735332Phase 2Terminated

Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma

Role: lead

NCT00730262Phase 2Terminated

Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme

Role: lead

NCT00422786Phase 2Completed

Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell Carcinoma

Role: lead

NCT00338026Phase 1Completed

A Phase I Study of ECO-4601 in Patients With Advanced Cancer

Role: lead

All 5 trials loaded